RxDoctor Payments Data

Susan Anzalone, MD

Neurology · Greenwood Village, CONPI 1043538085

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $105,528 of the $153,390 with a category attached, or 68.8%. Biogen accounts for 67.6% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2021 at $43,570 and has fallen 91.5% since, to $3,691 in 2025. Among neurology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$153,390in general payments, 2019–2025

Across 631 payments — averaging $243.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$104K
  • Genentech USA, Inc.$19K
  • Bristol Myers Squibb$14K
  • TG Therapeutics, Inc.$4K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Sanofi$2K
  • plus $7K from 33 others
$426,702in research payments, 2019–2025

Across 95 payments — averaging $4491.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi$239K
  • Genentech, Inc.$146K
  • Novartis$42K

What the payments were for

  • Consulting fees$23,11815%
  • Speaking & faculty fees$105,52869%
  • Travel & lodging$4,7053%
  • Food & beverage$19,57713%
  • Education$4610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$153,390 in reported general payments places this provider in the 90th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$562,032
Medicare patients
64
Services billed
10,126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab21$259,712
CopaxoneGlatiramer Acetate16$106,648
Dimethyl Fumarate13$2,060
Gabapentin15$204
Propranolol Hcl11$112

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$169$106,64816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 334 neurology providers in Colorado.

Other neurology in Greenwood Village

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →